MedPath

SOTROVIMAB FOR INJECTION

SOTROVIMAB FOR INJECTION

Authorization By Interim Order Revoked
DIN Number

02518341

Drug Class

Human

Market Date

Oct 8, 2021

Company
HC

GlaxoSmithKline Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02518341
AIG Number0163072001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Schedule D ,  COVID-19 - IO - Authorization ,  Prescription
A
ATC Code
J06BD05 SOTROVIMAB
Product Specifications
Dosage FormSolution
Route of AdministrationIntravenous
AHFS Classification08:18.24
Health Canada Classification

ACTIVE INGREDIENTS (1)

SOTROVIMABActive
Strength: 500 MG / 8 ML
Monograph: SOTROVIMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.